Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of YESCARTA 0.4 - 2 x 10 8 cells (axicabtagene ciloleucel) dispersion for infusion remains substantial in “the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy” and at the MA dosages.
|
Clinical Added Value
| moderate |
Considering:
- the updated data from the ZUMA-1 study, following a median follow-up of 63.1 months, which confirms the previously analysed results, particularly in terms of complete response (58% of patients in the mITT population, of whom 30% still in complete response at the time of the analysis after 60 months), and overall survival (median overall survival of 25.8 months in the mITT population; 5-year survival probability estimated to be 42.6%), in life-threatening clinical situations in which the treatment options are limited and do not enable remission to be envisaged,
- the role of YESCARTA (axicabtagene ciloleucel) compared to KYMRIAH (tisagenlecleucel), which remains difficult to determine given the major methodological limitations of the indirect comparison provided,
- the safety profile marked by significant short-term toxicity,
- additional experience with respect to the real-world data for YESCARTA (axicabtagene
ciloleucel) in the French DESCAR-T registry (27 activated centres, 756 treated patients, median follow-up of 15 months since eligibility), which are consistent with the clinical data (ZUMA-1),
- and the initial uncertainties identified, which persist despite the Transparency Committee’s requests, particularly with respect to:
- the exact effect size compared to historic management, in the absence of any robust comparison,
- maintenance of the clinical efficacy in the long term, particularly concerning achievement of full recovery for patients in lasting remission,
- and the absence of long-term safety data,
the Committee considers that its previous conclusions are not liable to be modified. On the basis of currently available data, the Committee deems that YESCARTA 0.4 - 2 x 108 cells (axicabtagene ciloleucel) dispersion for infusion provides a moderate clinical added value (CAV III) in terms of efficacy compared to the historic management of relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy, based on various chemotherapies.
|
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
Dsf4V5XaFw1rBEEN